Microvesicles derived from Alde-Low EPCs support the wound healing capacity of AT-MSCs

Tu, Tran Cam; Yamashita, Toshiharu; Kato, Toshiki; Nagano, Masumi; Trinh, Nhu‐Thuy; Hamada, Hiromi; Shimizu, Fujio; Ohneda, Kinuko; Matsuo-Takasaki, Mami; Onodera, Osamu

doi:10.1016/j.bbrc.2016.06.022

Cited by 7 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to the secreted proteins and trophic factors, MSCs also release small extracellular vesicles, i.e., microvesicles, into the injured microenvironment, which improve tissue regeneration. This phenomenon was also observed for EPC-derived extracellular vesicles (microvesicles and exosomes), which accelerate cutaneous wound healing by promoting angiogenesis [18,23,24]. Microvesicles are produced by a number of cells and are isolated from almost all organs and body fluids.…”

Section: Discussionmentioning

confidence: 72%

“…One of the main groups of extracellular vesicles, in addition to the well-known exosomes, is microvesicles, i.e., vesicles derived from the plasma membrane ranging in size from 100 to 1000 nm, shed from the cell surface. The contribution of microvesicles to wound healing was studied by many research groups [16][17][18]. In the regeneration of the ischemic tissue, microvesicles mediate the modulation of immune interactions, anti-inflammatory processes, and angiogenesis, as they contain proteins, RNA, miRNA, and trophic factors derived from parent cells [13].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Microvesicles from Human Immortalized Cell Lines of Endothelial Progenitor Cells and Mesenchymal Stem/Stromal Cells of Adipose Tissue Origin as Carriers of Bioactive Factors Facilitating Angiogenesis

Krawczenko

Bielawska‐Pohl

Paprocka

et al. 2020

Stem Cells International

View full text Add to dashboard Cite

Endothelial progenitor cells (EPCs) and mesenchymal stem/stromal cells (MSCs) are associated with maintaining tissue homeostasis and tissue repair. Both types of cells contribute to tissue regeneration through the secretion of trophic factors (alone or in the form of microvesicles). This study investigated the isolation and biological properties of microvesicles (MVs) derived from human immortalized MSC line HATMSC1 of adipose tissue origin and EPC line. The human immortalized cell line derived from the adipose tissue of a patient with venous stasis was established in our laboratory using the hTERT and pSV402 plasmids. The human EPC line originating from cord blood (HEPC-CB.1) was established in our previous studies. Microvesicles were isolated through a sequence of centrifugations. Analysis of the protein content of both populations of microvesicles, using the Membrane-Based Antibody Array and Milliplex ELISA showed that isolated microvesicles transported growth factors and pro- and antiangiogenic factors. Analysis of the miRNA content of isolated microvesicles revealed the presence of proangiogenic miRNA (miR-126, miR-296, miR-378, and miR-210) and low expression of antiangiogenic miRNA (miR-221, miR-222, and miR-92a) using real-time RT-PCR with the TaqMan technique. The isolated microvesicles were assessed for their effect on the proliferation and proangiogenic properties of cells involved in tissue repair. It was shown that both HEPC-CB.1- and HATMSC1-derived microvesicles increased the proliferation of human endothelial cells of dermal origin and that this effect was dose-dependent. In contrast, microvesicles had a limited impact on the proliferation of fibroblasts and keratinocytes. Both types of microvesicles improved the proangiogenic properties of human dermal endothelial cells, and this effect was also dose-dependent, as shown in the Matrigel assay. These results confirm the hypothesis that microvesicles of HEPC-CB.1 and HATMSC1 origin carry proteins and miRNAs that support and facilitate angiogenic processes that are important for cutaneous tissue regeneration.

show abstract

Section: Discussionmentioning

confidence: 72%

Section: Introductionmentioning

confidence: 99%

Microvesicles from Human Immortalized Cell Lines of Endothelial Progenitor Cells and Mesenchymal Stem/Stromal Cells of Adipose Tissue Origin as Carriers of Bioactive Factors Facilitating Angiogenesis

Krawczenko

Bielawska‐Pohl

Paprocka

et al. 2020

Stem Cells International

View full text Add to dashboard Cite

show abstract

“…transfected exosomes derived from Alde-Low EPCs (EMVs) into human ADSCs. After receiving EMVs, the ADSCs showed a remarkable elevation in the expression of the CXCR4 chemokine receptor in vitro , and CD45+ inflammatory cells were successfully recruited to the wound sites in vivo , promoting ischemic skin repair ( 75 ).…”

Section: Exosomes Derived From Stem Cell and Their Effect On Immune/i...mentioning

confidence: 99%

The Immunomodulatory effect of exosomes in diabetes: a novel and attractive therapeutic tool in diabetes therapy

Li,

Hu,

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Exosomes carry proteins, metabolites, nucleic acids and lipids from their parent cell of origin. They are derived from cells through exocytosis, are ingested by target cells, and can transfer biological signals between local or distant cells. Therefore, exosomes are often modified in reaction to pathological processes, including infection, cancer, cardiovascular diseases and in response to metabolic perturbations such as obesity and diabetes, all of which involve a significant inflammatory aspect. Here, we discuss how immune cell-derived exosomes origin from neutrophils, T lymphocytes, macrophages impact on the immune reprogramming of diabetes and the associated complications. Besides, exosomes derived from stem cells and their immunomodulatory properties and anti-inflammation effect in diabetes are also reviewed. Moreover, As an important addition to previous reviews, we describes promising directions involving engineered exosomes as well as current challenges of clinical applications in diabetic therapy. Further research on exosomes will explore their potential in translational medicine and provide new avenues for the development of effective clinical diagnostics and therapeutic strategies for immunoregulation of diabetes.

show abstract

“…[11][12][13][14][15][16][17][18][19][20][21] One study used ECFCs collected from human placenta. 22 Most (n = 59, 89%) studies administered ECFCs while 12 studies also included experiments with derivative products such as extracellular vesicles (ie, exosomes [23][24][25][26][27] or microvesicles 11,28 ), and/or conditioned media 7,[29][30][31][32] (Table 1). The majority of studies administered cells and/or derivative products via intravenous injection (n = 32; 48%) or intramuscularly (n = 15; 23%).…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

Human endothelial colony-forming cells in regenerative therapy: A systematic review of controlled preclinical animal studies

Liao

Zheng

Shorr

et al. 2020

Stem Cells Translational Medicine

View full text Add to dashboard Cite

Endothelial colony-forming cells (ECFCs) hold significant promise as candidates for regenerative therapy of vascular injury. Existing studies remain largely preclinical and exhibit marked design heterogeneity. A systematic review of controlled preclinical trials of human ECFCs is needed to guide future study design and to accelerate clinical translation. A systematic search of Medline and EMBASE on 1 April 2019 returned 3131 unique entries of which 66 fulfilled the inclusion criteria. Most studies used ECFCs derived from umbilical cord or adult peripheral blood. Studies used genetically modified immunodeficient mice (n = 52) and/or rats (n = 16). ECFC phenotypes were inconsistently characterized. While >90% of studies used CD31+ and CD45−, CD14 − was demonstrated in 73% of studies, CD146+ in 42%, and CD10+ in 35%. Most disease models invoked ischemia. Peripheral vascular ischemia (n = 29), central nervous system ischemia (n = 14), connective tissue injury (n = 10), and cardiovascular ischemia and reperfusion injury (n = 7) were studied most commonly. Studies showed predominantly positive results; only 13 studies reported ≥1 outcome with null results, three reported only null results, and one reported harm. Quality assessment with SYRCLE revealed potential sources of bias in most studies. Preclinical ECFC studies are associated with benefit across several ischemic conditions in animal models, although combining results is limited by marked heterogeneity in study design. In particular, characterization of ECFCs varied and aspects of reporting introduced risk of bias in most studies. More studies with greater focus on standardized cell characterization and consistency of the disease model are needed.

show abstract

Microvesicles derived from Alde-Low EPCs support the wound healing capacity of AT-MSCs

Cited by 7 publications

References 18 publications

Microvesicles from Human Immortalized Cell Lines of Endothelial Progenitor Cells and Mesenchymal Stem/Stromal Cells of Adipose Tissue Origin as Carriers of Bioactive Factors Facilitating Angiogenesis

Microvesicles from Human Immortalized Cell Lines of Endothelial Progenitor Cells and Mesenchymal Stem/Stromal Cells of Adipose Tissue Origin as Carriers of Bioactive Factors Facilitating Angiogenesis

The Immunomodulatory effect of exosomes in diabetes: a novel and attractive therapeutic tool in diabetes therapy

Human endothelial colony-forming cells in regenerative therapy: A systematic review of controlled preclinical animal studies

Contact Info

Product

Resources

About